Longterm impact of disclosing amyloid PET results to individuals with subjective cognitive decline
Jetske van der Schaar·Eva C. A. Asscher·Mariëtte A. van den Hoven·Leonie N. C. Visser·S. A. M. Sikkes·A. L. Bredenoord·Wiesje M. van der Flier·Mardou S. S. A. van Leeuwenstijn-Koopman·Elsmarieke van de Giessen·Calvin Trieu·Argonde C. van Harten·Heleen M.A. Hendriksen
Biomarker assessments increasingly inform the diagnostic evaluation and treatment decisions in Alzheimer disease (AD). However, evidence on the impact of amyloid positron emission tomography (PET) disclosure is primarily derived from studies of cognitively unimpaired trial participants with follow-up limited to 18 months. In contrast, long-term implications for individuals with cognitive concerns who seek medical evaluation in memory clinics remain unknown. We aimed to examine the psychosocial a